NCT05053802View on ClinicalTrials.gov

Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

March 21, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
Multiple Primary Lung Cancer
Interventions
COMBINATION_PRODUCT

Microwave ablation plus Camrelizumab

Tumor received treatment of microwave ablation and received no more than 16 cycles of Camrelizumab

DEVICE

Microwave ablation

Tumor received treatment of microwave ablation

Trial Locations (6)

200433

RECRUITING

Changhai Hospital, Shanghai

RECRUITING

Shanghai First People's Hospital, Shanghai

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

Unknown

RECRUITING

Ruijin Hospital, Shanghai

RECRUITING

Shanghai Tenth People's Hospital, Shanghai

RECRUITING

Renji Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER